• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Russian Journal of Gastroenterology, Hepatology, Coloproctology

    Russian Journal of Gastroenterology, Hepatology, Coloproctology

    JournalISSN 2658-6673

    年发文量

    研究主题

    论文(1151)

    排序
    1Combination of Hyaluronic Acid, Chondroitin Sulphate, and Poloxamer 407 for the Prevention and Treatment of Radiation Esophagitis (results of the RESOXX Multicenter Prospective Observational Study)
    D. S. Romanov, E. I. Turyaeva, S. N. Novikov, S. V. Golub, M. A. Ilin, D. A. Balaeva, G. A. Garyaev, P. R. Chowdhury, I. A. Cheremisina, M. A. Getman

    Aim: to evaluate the efficacy of an oral medical device — a fixed combination of hyaluronic acid, chondroitin sulphate, and the bioadhesive agent poloxamer 407 (Alfasoxx), on the incidence, course, and severity of radiation esophagitis symptoms in patients undergoing external beam radiotherapy for a primary malignancy.Materials and methods. A total of 215 patients were enrolled in the study, of whom 210 were included in the statistical analysis. Patients were divided into two groups: a treatment group (patients with manifestations of radiation esophagitis at study entry) and a prophylaxis group (patients enrolled on the start date of external beam radiotherapy). Seventeen oncologists from nine Russian cities participated in the study. Assessment methods included clinical and demographic evaluation, analysis of the incidence and distribution of radiation esophagitis risk factors, evaluation of radiation esophagitis severity according to CTCAE v. 5.0, assessment of radiation dose delivered to the esophagus, Alfasoxx dosage accounting for compliance, evaluation of the time to radiation esophagitis onset and its duration, analysis of swallowing function using the EAT-10 questionnaire, assessment of overall health-related quality of life using the EORTC QLQ-C30 questionnaire, and monitoring of adverse events.Results. Manifestations of radiation esophagitis were observed in 68.5 % of patients in the prophylaxis group; therefore, radiation esophagitis did not develop in 31.5 % of patients. Compared with the prophylaxis group, patients in the treatment group experienced a more severe course of the disease, with a mean radiation esophagitis severity score of 0.83 ± 0.53 vs. 0.52 ± 0.25 (p < 0.001). The mean EAT-10 score at baseline differed from that in the treatment group. However, from Visit 2 onward, mean scores aligned and demonstrated identical dynamics. A similar distribution was observed for overall quality of life as assessed by the EORTC QLQ-C30 questionnaire. The significant difference observed at the first visit (68.73 ± 15.69 points in the prophylaxis group vs. 58.24 ± 16.04 points in the treatment group; p < 0.001) was leveled by Visit 4 among patients who developed radiation esophagitis (79.96 ± 10.91 points in the prophylaxis group and 81.25 ± 11.03 points in the treatment group). Only one adverse event was identified during Alfasoxx administration: mild nausea after intake.Conclusion. The prophylactic administration of Alfazox concurrently with the initiation of external beam radiotherapy reduces the mean severity of radiation-induced esophagitis and shortens the duration of symptom manifestation.

    2026
    引用
    AI阅读
    加入学术空间
    2Therapeutic Potential of Natural Antioxidants (menthol, Gingerol, and D-Limonene) for Attenuation of Systemic Inflammatory Response Syndrome
    Ya. V. Kiseleva, E. A. Poluektova, R. V. Maslennikov, V. T. Ivashkin

    Introduction. Oxidative stress represents an imbalance between the production of reactive oxygen species and the body’s antioxidant defense system. One of the main causes of this condition is the inflammatory process. Collectively, oxidative stress and systemic inflammation are the key pathogenic mechanisms of numerous diseases. The intake of plant antioxidants can reduce oxidative stress and can be used for prevention.Aim: To analyze studies investigating the antioxidant properties of three plant components: peppermint essential oil, D-limonene (a component of citrus peel), and gingerol (a component of ginger).Key points. Modern research confirms the presence of pronounced antioxidant properties of peppermint essential oils, D-limonene, and gingerol in vitro, in experimental animal models, and in human cell cultures. These plant components have been shown to increase the quantity and activity of antioxidant enzymes, neutralize reactive oxygen species, reduce cellular damage, inhibit the synthesis of pro-inflammatory cytokines, and prevent apoptosis. Notably, in tumor cell cultures and animal models, D-limonene and gingerol demonstrate anti-tumor activity by increasing oxidative stress in cancer cells.Conclusion. Peppermint essential oil, D-limonene, and gingerol show promise as agents for the prevention and comprehensive treatment of various diseases associated with systemic inflammation and oxidative stress. However, further clinical research is necessary to confirm their efficacy and safety in humans.

    2026
    引用
    AI阅读
    加入学术空间
    3Biological Therapy for Complicated Forms of Eosinophilic Esophagitis
    V. O. Kaybysheva, A. S. Balabanov, A. I. Mokritskiy, E. V. Gorbachev, K. S. Maslyonkina, L. M. Mikhaleva, E. D. Fedorov, S. G. Shapovalianc

    Aim: to evaluate the efficacy and safety of dupilumab, a biologic therapy, in the treatment of refractory eosinophilic esophagitis complicated by esophageal strictures and food impaction, in patients who have failed prior therapy with proton pump inhibitors and topical glucocorticosteroids.Materials and methods. In a prospective study conducted from July 2024 to February 2026, 19 patients (2 females, 17 males) aged 19 to 70 years with a previously confirmed diagnosis of eosinophilic esophagitis were administered dupilumab at a dose of 300 mg once weekly subcutaneously for 12 weeks. Indications for dupilumab administration included a complicated disease course (esophageal strictures and narrowing, esophageal dissection, recurrent episodes of acute food impaction) in the setting of resistance to prior therapy with topical glucocorticosteroids and/or proton pump inhibitors. Additional criteria for initiating biologic therapy included coexisting T2-associated diseases, such as bronchial asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. All patients underwent assessment of dysphagia severity according to the Dysphagia Symptom Questionnaire (DSQ), calculation of the clinical and morphological disease activity index, esophagogastroduodenoscopy with esophageal biopsy (at least 6 biopsy specimens from the distal and middle/proximal esophagus), and histopathological examination of biopsy specimens both prior to treatment and at 12 weeks of therapy.Results. At 12 weeks of dupilumab therapy, complete resolution of dysphagia was observed in 9 (75 %) of 12 patients with dysphagia at baseline, and clinical remission (absence of any complaints) was achieved in 12 (63.2 %) of 19 patients. The mean DSQ score, reflecting dysphagia severity, decreased from 32.01 to 7.12 (p < 0.05). Endoscopic disease activity, as assessed by the EREхFS score, decreased from 5.0 [4.0; 7.0] to 1.0 [1.0; 3.0] points (p < 0.0001). Although the proportion of patients with strictures did not change significantly, an increase in esophageal diameter at the stricture site was observed (from 13.1 ± 5.8 mm to 16.1 ± 2.0 mm; p < 0.05). Histological remission (< 15 eosinophils per HPF, ×400) was achieved in 18 (94.7 %) of 19 patients. Adverse events included upper extremity joint pain (1 patient, 5.3 %), conjunctival dryness (2 patients, 10.5 %), and peripheral blood eosinophilia with elevated liver enzymes up to 3–4 times the upper limit of normal (1 patient, 5.3 %).Conclusions. Dupilumab therapy over 12 weeks leads to the achievement of clinical (63.2 %) and histological (94.7 %) remission in eosinophilic esophagitis.

    2026
    引用
    AI阅读
    加入学术空间
    4Gastroesophageal Reflux Disease and Barrett's Esophagus: Optimization of Patient Management and Cancer Prevention Measures (literature Review and Resolution of the Expert Council of the Russian Gastroenterolog
    V. T. Ivashkin, I. V. Maev, A. S. Trukhmanov, T. L. Lapina, D. N. Andreev, O. P. Alexeeva, S. A. Alekseenko,A. Yu. Baranovsky, O. V. Zayratyants, O. Yu. Zolnikova, K. V. Ivashkin, N. V. Korochanskaya,

    Aim: to summarize current clinical guidelines and meta-analyses data, and to present the main statements of the Expert Council of the Russian Gastroenterological Association regarding the optimization of endoscopic diagnosis, morphological verification, pharmacotherapy, and management strategies for patients with gastroesophageal reflux disease (GERD) and Barrett’s esophagus.Key points. In the Russian Federation, GERD is a highly prevalent disease: according to a meta-analysis involving over 30,000 individuals, the frequency of heartburn and/or regurgitation occurring once a week or more is 25 %. Proton pump inhibitors (PPIs) represent the cornerstone drug class for the treatment of GERD. Rebamipide targets altered epithelial permeability and mucosal inflammation. Combination therapy with PPIs and rebamipide improves symptoms in patients with non-erosive reflux disease, leading to positive morphological changes in the esophageal mucosa and improved control of nocturnal esophageal acid exposure. Ursodeoxycholic acid (UDCA) may be added to GERD therapy in the presence of biliary reflux or reflux gastritis. The clinical significance of GERD is determined not only by its high prevalence, chronic relapsing course, and impaired quality of life, but also by its precancerous potential. In individuals with GERD, the prevalence of Barrett’s esophagus is approximately 7 %, while the incidence of adenocarcinoma and/or high-grade dysplasia in the presence of low-grade dysplasia is 1.73% annually. Risk factors for the development of Barrett’s esophagus include male sex, age over 50 years, frequent GERD symptoms, tobacco smoking, obesity, and a positive family history. The management of patients with Barrett’s esophagus requires strict adherence to endoscopic and histological diagnostic protocols. Long-term PPI pharmacotherapy remains the standard of chemoprevention against neoplastic progression, demonstrating superiority over surgical treatment. Timely screening of high-risk individuals and adherence to endoscopic surveillance intervals enable the detection of dysplasia and esophageal adenocarcinoma at early, treatable stages.Conclusion. The Expert Council members proposed algorithms for the treatment of acute GERD exacerbation and maintenance therapy, as well as for the diagnosis and surveillance of patients with Barrett’s esophagus, taking into account current evidence and principles of evidence-based medicine. The literature review and the proposed algorithms aim to provide informational support for general practitioners, internists, gastroenterologists, and endoscopists in order to improve the quality of healthcare delivery and ensure effective prevention of esophageal adenocarcinoma.

    2026
    引用
    AI阅读
    加入学术空间
    5Efficacy and Safety of an 8-Week Antiviral Therapy for Chronic Hepatitis C with Ravidasvir and Sofosbuvir
    P. O. Bogomolov, A. O. Bueverov, N. A. Barsukova, M. M. Korshunov, A. Yu. Demyanov, E. A. Isaeva, O. I. Nikitin

    Introduction. Hepatitis C virus (HCV) genotype 3 is associated with accelerated progression of liver disease; therefore, individuals infected with this genotype represent a clinically significant subgroup of patients. Despite the high efficacy of direct-acting antivirals, the optimal duration of therapy remains a subject of debate.Aim. To evaluate, in a real-world clinical setting, the efficacy and safety of an 8-week treatment regimen consisting of ravidasvir (200 mg) and sofosbuvir (400 mg) once daily in treatment-naive patients with chronic hepatitis C virus genotype 3 (HCV-3) infection and F0–F2 liver fibrosis (according to the METAVIR score).Materials and methods. This prospective, single-cohort, observational study (ClinicalTrials.gov, NCT07316842) enrolled 30 patients with HCV-3; the final per-protocol analysis included 29 patients who completed the full course of antiviral therapy and were available for the assessment of sustained virological response 12 weeks after treatment cessation (SVR12). The diagnosis of HCV-3 was verified in accordance with the Clinical Guidelines “Chronic Hepatitis C”, approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. The mean age of the patients was 40.4 ± 7.1 years, and 65.5 % were men. The stage of liver fibrosis was determined by transient elastography using the FibroScan device (Echosens, France). The distribution of fibrosis stages was as follows: F0 — 44.8 %, F1 — 48.3 %, and F2 — 6.9 %. The primary endpoint was the achievement of SVR12, while the secondary endpoints included the achievement of aviremia 4 weeks after antiviral therapy completion (SVR4), viral load dynamics, changes in ALT and AST activity during treatment, as well as the safety and tolerability of the antiviral therapy.Results. In patients with HCV-3 and F0–F2 liver fibrosis (according to the METAVIR score), SVR12 was registered in 28 out of 29 patients (96.6 %; 95% CI: 82.8–99.4). SVR4 was achieved in 24 out of 25 patients with available data (96.0 %; 95% CI: 80.5–99.3). The median viral load decreased from 8.3 × 105 IU/mL at baseline to an undetectable level after 4 weeks of treatment and remained at this level at the time of SVR12 assessment. The median ALT activity decreased from 115.2 to 18.0 U/L, and AST activity decreased from 66.0 to 23.3 U/L (p < 0.001 for both parameters). No serious adverse events or treatment discontinuations due to adverse events were registered.Conclusion. The shortened 8-week antiviral therapy regimen with a combination of ravidasvir (200 mg) and sofosbuvir (400 mg) once daily in patients with HCV-3 without advanced liver fibrosis demonstrates high efficacy and a favourable safety profile in this cohort.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1151 篇论文

    高被引作者

    作者引用发文
    Ivashkin Vt883242
    Alexander Trukhmanov55697
    Arkadiy A. Sheptulin550109
    T. L. Lapina46076
    Alexey Okhlobystin34822
    I V Maev31237
    I. V. Mayev26953
    Elena Poluektova26435
    N. V. Korochanskaya22935
    Vladislav V. Tsukanov22627

    高产作者

    作者引用发文
    Ivashkin Vt883242
    Arkadiy A. Sheptulin550109
    Alexander Trukhmanov55697
    T. L. Lapina46076
    M. V. Mayevskaya11870
    O. S. Shifrin21057
    I. V. Mayev26953
    Olga Storonova12138
    I V Maev31237
    Ye.A. Poluektova6436

    相关期刊

    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology
    Euroasian journal of hepato-gastroenterology
    EC gastroenterology and digestive system
    Open journal of gastroenterology
    Der Gastroenterologe
    Epistīmonika Chronika
    The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
    Gastro-News
    Russian Journal of Evidence-Based Gastroenterology
    DEN Open